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Background. Due to allowing of methylisothiazolinone (MI) in cosmetics, cleaning products, and paints, an epidemic of MI-
hypersensitivity emerged. Patch testing Kathon CG (3:1 mixture of methylchloroisothiazolinone and methylisothiazolinone,
MCI/MI) does not correctly detect MI contact allergy, due to the low concentration of MI in the test material. Methods. A
retrospective survey was performed to estimate the prevalence of MCI/MI hypersensitivity in 14693 patients tested consecutively
between 1993 and 2014. Moreover, currently 314 patients were prospectively tested with the allergens MCI/MI and with MI during
one year. Results. MCI/MI hypersensitivity increased retrospectively from 0.5% to 6.0%. By current prospective testing we detected
25 patients (8%) with MCI/MI and/or MI positive reactions. Out of the 25 patients 10 were only MCI/MI positive, 9 were only
MI positive, and 6 were MCI/MI and MI positive. If MI had not been tested separately, MI contact allergy would have missed in
36% of all detected cases and in 2.8% of the total 314 patients. Conclusions. The frequency of MCI/MI hypersensitivity is increasing
also in Hungary. We confirm that, in order to detect MI contact allergy, it needs to be tested separately. A further increase of MI
hypersensitivity might be expected in the future as products containing MI are still widely available.
1. Introduction
Due to the introduction of Kathon CG (MCI/MI) in the
midseventies a worldwide epidemic of contact allergy to it
emerged. This preservative became widely used in cosmetics
and household cleaning products because of its efficacy. Con-
tact allergy toMCI/MI—mostly provoked by cosmetics—was
first reported by de Groot et al. [1]. Frosch and Schulze-Dirks
[2] estimated the sensitization rate between 0.4% and 11.1%—
with a mean of 3.0%—in their European multicentre study
[3] which was similar to our own data (3.4%) observed in the
same period [4].
At the beginning of the newmilleniumMIwas allowed as
a separate preservative in industrial products (paints, glues)
and initially gained attention as an occupational allergen, and
it still is nowadays [5]. Due to its use in cosmetics, a new and
unprecedented epidemic arose in Europe, in the USA, and in
Asia [6–10].
Unfortunately, MCI/MI tested in routine patch test series
does not correctly detect MI hypersensitivity, because of
the low concentration of MI in the mixture. So, MCI/MI
testing in itself did not detect a quite high percent of the MI
allergy [9]. Uter et al. already suggested in 2012 the routine
separate testing ofMI and including it into the standard patch
test series [11]. Recently, the recommended MI patch test
concentration became 2000 ppm (or 0.2% aqua) [12–14]. We
here present our experience with MCI/MI and MI contact
allergy and the data in Hungary.
2. Material and Methods
(1) We retrospectively reviewed the prevalence of MCI/MI
hypersensitivity (European Baseline series Brial Allergen
GmbH, Germany, chamber: Curatest) in 14693 patients
tested consecutively from 1993 until 2014 at the Allergy Out-
patient Unit of the Department of Dermatology, Venereology
and Dermatooncology of the Semmelweis University.
(2) Moreover, 314 patients were prospectively tested
consecutively between February 1st, 2014, and January 30th,
2015, with the standard allergens MCI/MI 0.01% aqua and
MI 0.2% aqua (ChemotechniqueDiagnostics, Vellinge, Sweden,
chamber: IQ Chambers).We performed parallel testing with
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the European Baseline series (AllergEAZE, Brial Allergen
GmbH, Germany, chamber: Curatest including the Brial
MCI/MI/0.01% aqua/contact allergen), as well. As we had
not tested MI separated in routine patch series before,
comparative data concerning the past years have not been
available.
The occlusion time by testing was 48 h; the allergens were
applied on the back. Evaluation of the test was performed at
the 60thminute of the occlusion and then onD2, D3, D4, and
D7. Reactions were taken as positive 1+ or more intense.
3. Results
3.1.MCI/MIHypersensitivity 1993–2014. Assessing the preva-
lence ofMCI/MI hypersensitivity in our 14693 patients tested
consecutively between 1993 and 2014, we detected waver-
ing percent rates (MCI/MI hypersensitive patients/tested
patients in the year). Starting from a value of 0.5% (1993:
5/1011 patients), it reached 6.7% (2011: 27/401 patients), 5.3%
(2012: 22/413 patients), 3.3% (2013: 13/390 patients), and 6.0%
(2014: 23/383 patients) (Table 1, Figure 1).
3.2. Testing with MCI/MI (0.01% Aqua) and MI (0.2% Aqua)
and Parallel Testing with the Standard Brial Baseline Series
(Including MCI/MI Allergen) between February 1st, 2014, and
January 30th, 2015. The mean age of the 314 tested patients
was 48.9 years (range: 13–88 years). There were 79 men with
a mean age of 50.6 years (range: 18–88 years) and 235 women
with a mean age of 48.4 years (range: 13–88 years).
Regarding the patch test containing MCI/MI, we did not
find any differences in the results between the Brial and the
Chemotechnique allergens.
We detected 25 patients (8%) with MCI/MI and/or MI
positivity: 17 women and 8 men. MCI/MI hypersensitivity
was detected in 16 cases (5.1%) and MI hypersensitivity in
15 cases (4.8%). Regarding parallel positivities: out of the
25 patients 10 were only MCI/MI positive, 9 were only MI
positive, and 6 were concurrently MCI/MI and MI positive.
Thus,MI positivity withoutMCI/MI positivity was found
in 36% of these or in 2.8% of the whole tested population of
314 patients. Among the MI sensitized patients the mean age
was 39 years (Tables 2(a), 2(b), and 2(c)). Regarding local-
isation of contact dermatitis, we observed by MI sensitive
patients skin symptoms first of all on the hands, the face, and
the scalp. Most typical sources of the allergens were liquid
soaps, baths, hair shampoos, hand and face creams, and wet
cleansing wipes—mostly rinse-off products.
According to occupational dermatitis, we identified only
four patients: two patients (hairdresser and washer-up) with
only MI hypersensitivity, one patient (anaesthetist assistant)
with both MCI/MI and MI hypersensitivity, and one patient
with only MCI/MI hypersensitivity (maid).
Associated contact allergies were detectedwith, for exam-
ple, fragrancemix I, fragrancemix II, propylene glycol, nickel
sulfate, and paraphenylenediamine (PPD) in 18 patients.
There were 3 patients in the MCI/MI and MI sensitive group
and 4 patient in the MI sensitive group without associated
contact hypersensitivities (Tables 2(a), 2(b), and 2(c)).
Table 1: MCI/MI hypersensitivity 1993–2014.
Year Tested patients/year MCI/MI hypersensitivepatients/year %
1993 1011 5 0.5
1994 636 2 0.3
1995 839 16 1.9
1996 1099 22 2.0
1997 938 13 1.4
1998 802 7 0.9
1999 834 6 0.7
2000 797 16 2.0
2001 799 7 0.9
2002 698 11 1.6
2003 701 7 1
2004 670 12 1.8
2005 637 7 1
2006 612 6 1
2007 538 17 3.1
2008 514 18 3.5
2009 512 10 1.9
2010 480 16 3.3
2011 401 27 6.7
2012 413 22 5.3
2013 390 13 3.3
2014 383 23 6.0
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Figure 1: MCI/MI hypersensitivity data in percent (MCI/MI
hypersensitive patients/tested patients in the year) at the Allergy
Outpatient Unit of the Department of Dermatology, Venereology
andDermatooncology of the SemmelweisUniversity 1993–2014 (𝑛 =
14693).
4. Discussion
In 1987 methylisothiazolinone was considered to be a weak
sensitizer in the animal experiments of Bruze et al. [15].
By allowing much higher concentrations use than before an
unprecedented allergy epidemic occurred and still occurs
worldwide. Among the problematicMI-containing products,
cosmetics have been in a leading position since 2005, as the
concentration of MI was authorized in both leave-on and
rinse-offproducts up to 100 ppm [16].Hair care products even
proved to be one of the most problematic ones [6, 7, 9].
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Table 2: Localisation of clinical symptoms and associated sensitivities of MCI/MI and/or MI hypersensitive patients (total tested patients,
𝑛 = 314).
(a) MCI/MI hypersensitive patients: localisation of clinical symptoms and associated sensitivities (𝑛 = 10)
P Age Gender Dg Localisation ofskin symptoms
Patch test hypersensitive
reaction Sources of the allergen Associated sensitivities
MCI/MI MI
(1) 78 W ACD Hands 2+-3+ − Liquid soap, handcreams
Propolis, Balsam Peru
thiuram mix
(2) 70 M ACD Trunk, limbs 2+ − Baths, body lotion Propylene glycol,quaternium 15, wool alcohol
(3) 58 M Dysidrosis Hands 3+ − Liquid soap Propylene glycol
(4) 40 W ACD Eyelids 2+ − Hair dye PPD, nickel sulfate, cobaltchloride
(5) 40 M ACD Hands 2+ − Liquid soap Fragrance mix II
(6) 27 W ACD Neck, scalp 2+ − Hair shampoo Nickel sulfate, thiomersal
(7) 68 W ACD/stasisdermatitis Legs 2+ − Wet cleansing wipes
Wool alcohol, wood tar mix,
Balsam Peru
(8) 55 M ACD/stasisdermatitis Legs 2+ − Wet cleansing wipes
Propylene glycol, fragrance
mix I, tixocortol pivalate
(9) 57 W ACD Hands 2+-3+ − Liquid soap Nickel sulfate, cobaltchloride
(10) 40 W ACD Hands∗ 2+ − Household cleaners Nickel sulfate, cobaltchloride
W: woman, M: man, P: patient, Dg: diagnosis, and ACD: allergic contact dermatitis.
∗Maid, −: negative.
(b) MCI/MI and MI hypersensitive patients: localisation of clinical symptoms and associated sensitivities (𝑛 = 6)
P Age Gender Dg Localisation ofskin symptoms
Patch test hypersensitive reaction Sources of the allergen Associated sensitivities
MCI/MI MI
(1) 25 W ACD Hands 3+ 2+-3+ Wet cleansing wipes, hand creams −
(2) 17 W ACD Hands 2+ 1+-2+ Hand creams −
(3) 56 W ACD Hands, legs 2+ 2+ Baths, dish washing liquids Fragrance mix I,propylene glycol
(4) 43 W ACD Hands∗ 3+ 2+-3+ Liquid soaps Nickel sulfate
(5) 54 W ACD Eyelids 2+ 2+ Facial cleansing wipes, hair shampoo Nickel sulfate
(6) 16 W ACD Trunk andlimbs 1+-2+ 1+-2+ Baths, body lotion −
W: woman, M: man, P: patient, Dg: diagnosis, and ACD: allergic contact dermatitis.
∗Anaesthetist assistant, −: negative.
(c) MI hypersensitive patients: localisation of clinical symptoms and associated sensitivities (𝑛 = 9)
P Age Gender Dg Localisation ofskin symptoms
Patch test hypersensitive
reaction Sources of the allergen Associated sensitivities
MCI/MI MI
(1) 16 W ACD Scalp − 2+ Hair dye −
(2) 61 M ACD Hands − 2+-3+ Liquid soaps −
(3) 66 W ACD Eyelids − 2+ Hair shampoo, facecreams Wood tar mix, tixocortol pivalate
(4) 32 M ACD Hands − 2+ Hair shampoo, baths −
(5) 21 W ACD Scalp − 2+ Hair shampoo, hair dye PPD
(6) 47 M ACD Hands∗ − 3+ Hair shampoo PPD, propylene glycol, BalsamPeru, budesonide
(7) 50 W ACD Face − 1+-2+ Face creams Fragrance mix I, fragrance mix II
(8) 42 W ACD Hands∗∗ − 2+-3+ Dish washing liquids,hand creams
Potassium dichromate, nickel
sulfate, wood tar mix, thiuram
mix, fragrance mix I, fragrance
mix II
(9) 40 M ACD Hands − 2+ Liquid soaps −
W: woman, M: man, P: patient, Dg: diagnosis, and ACD: allergic contact dermatitis.
∗Hairdresser, ∗∗washer-up, and −: negative.
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Apart from the high concentration of MI used, the
increase of MI sensitization can also be explained by the fact
that the number of cosmetics containing this preservative
(baby care products, baths, make-up, hair, nail, skin care, and
sun protection products) has doubled in the USA between
2007 and 2010. Castanedo-Tardana even nominated MI as
the “Allergen of the Year 2013” [7]. MI is in the focus of
allergology in our days as well, because of further increasing
of contact sensitization, caused by leave-on and by rinse-
off cosmetic products [12–17]. The widespread use of MI in
several products and cumulative exposures to MI may also
be responsible for the high percent of sensitization to it.
According to a recent study focusing on contact sensitization
in patients with suspected cosmetic intolerance,MIwas by far
the leading allergen provoking contact sensitization among
preservatives [9, 17].
Another recent study examined whether the allowed
concentrations of MI in cosmetic rinse-off products have the
potential to cause allergic contact dermatitis. According to
the results, the rinse-off products with 50 ppm MI or more
are not safe for the consumers [18].
In our large study population tested between 1993 and
2014 the prevalence of MCI/MI hypersensitivity gave waver-
ing percent rates, but we detected an increasing rate from the
beginning to the endpoint. In this process presumably theMI
component of the allergen played an important role [14, 19].
Moreover, we started prospective MI patch testing sepa-
rately as a routine examination and followed the test results
for one year. The 4.8% prevalence of MI hypersensitivity
is, though high, may be considered as rather moderate
compared to other European data [11, 16–22]. Among the
MI sensitized patients the mean age was 39 years. Regarding
clinical symptoms, we observed contact dermatitis first of all
on the hands, the face, and the scalp [14, 23–25]. The sources
of the allergens were mostly rinse-off products (liquid soaps,
baths, and hair shampoos).
Interestingly, MI contact allergy without MCI/MI posi-
tivity was found in 36% among the patients with positive test
reactions to MCI/MI, MCI/MI and MI, and only MI and in
2.8%of the total tested 314 patients.These patientswould have
been missed if MI had not been tested separately.
In conclusion, MCI/MI and MI contact allergy is a hot
topic and an ongoing problem also in Hungary. Despite the
restrictions, further increase of MI hypersensitivity may also
be expected in the near future as products containing MI
are still available widely. The new results worldwide support
recommendations for a review of the regulations relating to
MCI/MI and/or MI in cosmetics and household products
[10, 14, 17, 18].
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